Definium Therapeutics' stock surged 5.65% during Monday's trading session, mirroring gains across the psychedelic drug development sector following a significant regulatory announcement from the White House.

The rally was triggered by President Donald Trump's executive order signed on Saturday, which directs health regulators to accelerate reviews of psychedelic drugs like ibogaine and commits $50 million for related research. The order provides regulatory benefits including faster FDA review timelines for breakthrough therapy drugs and enables patient access through the Right to Try Act for experimental treatments.

Definium Therapeutics, which is developing LSD-based treatments for major depressive disorder and generalized anxiety disorder currently in Phase 3 trials, stands to benefit directly from these regulatory changes. Analysts note that the executive order represents a substantial reduction in regulatory risk for the emerging psychedelic therapy sector and could lead to faster commercialization timelines for Definium's pipeline.